10:00 ET -- Bristol Myers Squibb is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Bristol Myers Squibb is buying Mirati Therapeutics in a deal that values the oncology developer at up to $5.8 billion. The biopharmaceutical company on Sunday said that it had entered into a definitive merger agreement with Mirati under which it would pay $58.00 a share in cash. Mirati stockholders will also receive one non-tradable contingent value right per share, potentially worth $12.00 a share in cash. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

October 09, 2023 10:15 ET (14:15 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Mirati Therapeutics Charts.
Mirati Therapeutics (NASDAQ:MRTX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Mirati Therapeutics Charts.